Nanolock Sensor Detects Cancer Driver Mutation
By LabMedica International staff writers Posted on 24 Jul 2017 |
Researchers have developed an accurate and sensitive “nanolock-nanopore” method that successfully diagnosed a known cancer driver mutation with results at the level of single DNA molecules in tumor tissues of thyroid cancer patients. The method can be adapted to detect a broad spectrum of both transversion and transition mutations, with applications from early diagnostics to individualized targeted therapy and monitoring.
Cancer driver mutations assist in the initiation and progression of cancers, many of which can be stopped in time if caught early enough. The current method for detecting driver mutations is real-time PCR, but it is not accurate enough to detect these genetic changes reliably. Researchers have developed methods to read the genetic sequence by moving it through a nanopore, but also this method is not accurate enough on its own.
Building on their previous work, Prof. Li-Qun Gu, of University of Missouri (Columbia, MO, USA), and colleagues sought a way to better pinpoint these mutations, and with single-molecule resolution. They developed and investigated their novel method using as a test case the known BRAF V600E mutation. The team has now found that mutant DNA carrying a nanolock undergoes a unique type of unzipping when it moves through the nanopore. Detecting this activity resulted in a highly accurate and sensitive nanopore fingerprint for the BRAF mutation in the thyroid cancer patients’ tumor tissue samples.
The researchers anticipate the approach, once integrated with a miniature high-throughput device, could enable PCR-free detection of various disease-causing mutations for diagnosis and prognosis.
The study, by Wang Y et al, was published July 5, 2017, in the journal ACS Sensors.
Related Links:
University of Missouri
Cancer driver mutations assist in the initiation and progression of cancers, many of which can be stopped in time if caught early enough. The current method for detecting driver mutations is real-time PCR, but it is not accurate enough to detect these genetic changes reliably. Researchers have developed methods to read the genetic sequence by moving it through a nanopore, but also this method is not accurate enough on its own.
Building on their previous work, Prof. Li-Qun Gu, of University of Missouri (Columbia, MO, USA), and colleagues sought a way to better pinpoint these mutations, and with single-molecule resolution. They developed and investigated their novel method using as a test case the known BRAF V600E mutation. The team has now found that mutant DNA carrying a nanolock undergoes a unique type of unzipping when it moves through the nanopore. Detecting this activity resulted in a highly accurate and sensitive nanopore fingerprint for the BRAF mutation in the thyroid cancer patients’ tumor tissue samples.
The researchers anticipate the approach, once integrated with a miniature high-throughput device, could enable PCR-free detection of various disease-causing mutations for diagnosis and prognosis.
The study, by Wang Y et al, was published July 5, 2017, in the journal ACS Sensors.
Related Links:
University of Missouri
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer